Incyte's FDA Approval
Based on encouraging data from the REACH1 trial the FDA approved a label expansion of the Incyte (INCY) product Jakafi (ruxolitinib) for graft-versus-host disease (GVHD) in people 12 years and older.
The FDA previously granted Jakafi Breakthrough therapy designation and orphan drug status for acute GVHD.
GVHD is a condition that might occur after an . . .
This content is for paid subscribers.
Today’s Highlights May 29, 2019